Compare DOMH & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMH | ATYR |
|---|---|---|
| Founded | 1967 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.1M | 49.2M |
| IPO Year | 2010 | 2015 |
| Metric | DOMH | ATYR |
|---|---|---|
| Price | $2.20 | $0.43 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $3.67 |
| AVG Volume (30 Days) | 154.3K | ★ 605.1K |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | ★ 23.45% | N/A |
| EPS Growth | ★ 34.03 | 6.98 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $123,104,000.00 | $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 578.41 | N/A |
| 52 Week Low | $1.91 | $0.40 |
| 52 Week High | $8.40 | $6.50 |
| Indicator | DOMH | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 31.05 | 34.21 |
| Support Level | N/A | $0.40 |
| Resistance Level | $3.29 | $0.59 |
| Average True Range (ATR) | 0.12 | 0.04 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 12.82 | 0.14 |
Dominari Holdings Inc is a holding company that, through its various subsidiaries, is engaged in wealth management, investment banking, sales and trading, asset management, and insurance. In addition to capital investment, Dominari provides management support to the executive teams of its subsidiaries, helping them to operate efficiently and reduce costs under a streamlined infrastructure. The Company operates in two reportable business segments: Dominari Financial and Legacy AIkido, with the majority of revenue from Dominari Financial.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).